Cover Image

LIPID-DRUG CONJUGATES innovation and applications.

Lipid-Drug Conjugates: Innovation and Applications highlights the most recent advances and clinical applications of nano lipid-drug conjugates for enhanced drug delivery and targeting in the treatment of cancer, glioblastoma, Alzheimer's, AIDS, and bacterial diseases. In addition, various conju...

Full description

Bibliographic Details
Corporate Author: ScienceDirect (Online service)
Other Authors: Das, Malay K.
Format: eBook
Language:English
Published: [S.l.] : Academic Press, 2025.
Subjects:
Drug delivery systems.
Lipids.
Drug Delivery Systems
Lipids
Systèmes d'administration de médicaments.
Lipides.
lipid.
Electronic books.
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Front Cover
  • Lipid-Drug Conjugates: Innovation and Applications
  • Copyright Page
  • Contents
  • List of contributors
  • Preface
  • 1 Innovations in lipid-drug conjugates
  • 1 Lipid-drug conjugates: application of lipid in drug delivery
  • 1.1 Introduction
  • 1.2 The concept of lipid-drug conjugates
  • 1.3 Various lipid moieties used in lipid-drug conjugate designing
  • 1.3.1 Fatty acids
  • 1.3.2 Glycerides
  • 1.3.3 Phospholipids
  • 1.3.4 Steroids
  • 1.3.5 Fat-soluble endogenous molecules
  • 1.4 Method of preparation
  • 1.4.1 Lipid-drug conjugates with noncovalent linkages
  • 1.4.2 Lipid-drug conjugates with covalent linkages: without spacer
  • 1.4.3 Lipid-drug conjugates with covalent linkages: with spacer
  • 1.5 Incorporation of lipid-drug conjugates in delivery systems
  • 1.5.1 High-pressure homogenization
  • 1.5.2 Microemulsion technique
  • 1.5.3 Solvent emulsification evaporation
  • 1.5.4 Solvent emulsification-diffusion
  • 1.6 Delivery system for lipid-drug conjugates
  • 1.6.1 Liposomes
  • 1.6.2 Emulsions
  • 1.6.3 Micelles
  • 1.6.4 Lipid nanoparticles
  • 1.6.5 Polymeric nanoparticles
  • 1.7 Advantages of lipid-drug conjugates
  • 1.7.1 Targeted drug delivery
  • 1.7.2 Enhancement of oral bioavailability
  • 1.7.3 Overcoming drug resistance
  • 1.7.4 Achieving extended drug release
  • 1.7.5 Enhance tumor targeting and reduce toxicity
  • 1.8 Applications of lipid-drug conjugates
  • 1.9 Conclusion and future perspective
  • References
  • 2 Lipid-drug conjugates: conjugation methods and therapeutic benefits
  • 2.1 Introduction
  • 2.2 Lipid-drug conjugation methods
  • 2.2.1 Lipid-drug conjugates with covalent bonds
  • 2.2.1.1 Lipid-drug conjugates through covalent bonds without spacer
  • 2.1.1.1 Conjugation through Ester bonds
  • 2.1.1.2 Conjugation through Hydrazone bonds
  • 2.1.1.3 Conjugation through amide bonds.
  • 2.1.1.4 Conjugation through disulfide bonds
  • 2.2.1.2 Lipid-drug conjugates through covalent bonds with spacer/linker
  • 2.2.2 Lipid-drug conjugates with non-covalent bonds
  • 2.3 Therapeutic benefits of lipid-drug conjugates
  • 2.3.1 Low-density lipoproteins-assisted targeted drug delivery
  • 2.3.2 Low-density lipoproteins-assisted tumor targeting and reduce toxicity
  • 2.3.3 Low-density lipoproteins for countering drug resistance
  • 2.3.4 Low-density lipoproteins for oral drug bioavailability enhancement
  • 2.3.5 Low-density lipoproteins for boosting pharmacological activity
  • 2.4 Current status quo on clinical trials of lipid-drug conjugates
  • 2.5 Conclusion and future perspectives
  • References
  • Further reading
  • 3 Route of administration and cellular interaction of lipid drug conjugates
  • 3.1 Introduction
  • 3.2 Delivery system of lipid drug conjugations
  • 3.2.1 Emulsion
  • 3.2.2 Liposomes
  • 3.2.3 Micelles
  • 3.2.4 Lipid nanoparticles
  • 3.2.5 Polymeric nanoparticles
  • 3.3 Routes of administration
  • 3.3.1 Oral
  • 3.3.1.1 Lipid-drug conjugation approaches for oral lipid-drug conjugates
  • 3.3.1.2 Mechanisms involved in enhancing oral bioavailability of oral lipid-drug conjugates
  • 3.3.1.3 Therapeutic utilities of oral lipid-drug conjugates
  • 3.3.2 Intravenous
  • 3.3.2.1 Therapeutic utilities of intravenous lipid-drug conjugates
  • 3.3.3 Subcutaneous
  • 3.3.3.1 Therapeutic utilities of subcutaneous lipid drug conjugations
  • 3.4 Cellular interaction of lipid drug conjugates
  • 3.4.1 Cellular uptake by interacting with lipids
  • 3.4.2 Cellular uptake by interacting with proteins in cell membrane
  • 3.4.3 Cellular uptake of saccharides located in cell membrane
  • 3.4.4 Through disulfide exchange
  • 3.5 Conclusion
  • References
  • 4 Lipid-drug conjugates for enhanced drug delivery and targeting
  • 4.1 Introduction.
  • 4.2 Lipid-drug conjugate
  • 4.3 Selection of drugs, lipids, solvents, and possible linkers in the formulation of lipid-drug conjugates
  • 4.4 Application of lipid-drug conjugates: a flourishing approach for enhanced drug targeting
  • 4.4.1 Enhancing oral drug delivery
  • 4.4.1.1 Leveraging lipid metabolism pathways
  • 4.4.1.2 Enhanced cell membrane interaction
  • 4.4.2 Improve the delivery of anticancer drugs
  • 4.4.2.1 Enhanced tumor targeting
  • 4.4.2.2 Controlled release in the tumor microenvironment
  • 4.4.2.3 Reduced toxicity of anticancer drugs
  • 4.4.3 Overcoming drug resistance
  • 4.4.4 Enhancing central nervous system drug delivery with lipid-drug conjugates
  • 4.4.4.1 Increasing lipophilicity
  • 4.4.4.2 Receptor-mediated transport
  • 4.4.5 Enhancing delivery of gene medicines with lipid-drug conjugates
  • 4.4.5.1 Role of lipid-drug conjugates in gene medicine delivery
  • 4.4.5.2 Lipid-mediated small interfering RNA delivery
  • 4.5 Mechanism of drug release from lipid-drug conjugates
  • 4.5.1 pH-responsive lipid-drug conjugates
  • 4.5.2 Enzyme-responsive lipid-drug conjugates
  • 4.5.3 Redox-responsive lipid-drug conjugates
  • 4.5.4 Reactive oxygen species-responsive lipid-drug conjugates
  • 4.6 Conclusion and future perspectives
  • Acknowledgment
  • Conflict of interest
  • References
  • Further reading
  • 5 Antibody-conjugated lipid nanoparticles as a targeted drug delivery system for hydrophobic drugs
  • 5.1 Introduction
  • 5.2 Hydrophobic drugs and their delivery challenges
  • 5.2.1 Techniques for solubility enhancement of hydrophobic drugs
  • 5.3 Lipid nanoparticles, and antibodies as targeting agents
  • 5.3.1 Liposome
  • 5.3.2 Solid lipid nanoparticles
  • 5.3.3 Nanostructured lipid carriers
  • 5.3.4 Lipid-polymer hybrid nanoparticles
  • 5.3.5 Nanoemulsions
  • 5.3.6 Lipid drug conjugates nanoparticles
  • 5.3.7 Transferosomes.
  • 5.4 Antibodies as targeting agents
  • 5.4.1 Overview of antibody structure and function
  • 5.4.2 Design for antibody-targeted nanoparticles
  • 5.5 Conjugation techniques for ACNP production
  • 5.5.1 Adsorption
  • 5.5.2 Binding by adapter molecules
  • 5.5.3 Covalent strategies
  • 5.5.4 Carbodiimide chemistry
  • 5.5.5 Maleimide chemistry
  • 5.5.6 Click chemistry
  • 5.5.7 Multivalent effect of antibody-conjugated nanoparticles
  • 5.6 Challenges in the development of ACNPs for medical use
  • 5.7 Diagnostic applications of ACNPs
  • 5.7.1 In vitro diagnostic applications
  • 5.7.1.1 Cell sorting
  • 5.7.1.2 Sensing
  • 5.7.2 In vivo diagnostic applications
  • 5.7.2.1 Imaging
  • 5.7.2.2 Therapeutic applications
  • 5.7.2.2.1 Targeted drug delivery
  • 5.7.2.2.2 Tumor therapy
  • 5.7.2.2.3 Brain targeting
  • 5.7.2.2.4 Gene delivery and tissue repair
  • 5.7.2.2.5 Inflammatory and infectious diseases
  • 5.7.2.2.6 Pulmonary diseases
  • 5.7.2.2.7 Other applications
  • 5.8 Future perspectives
  • 5.9 Conclusion
  • Author contributions
  • Declaration of competing interest
  • Acknowledgments
  • References
  • 6 Pharmacokinetics of lipid drug conjugates
  • 6.1 Introduction
  • 6.2 Structural features, conjugation methods, and delivery carriers
  • 6.2.1 Different types of conjugation strategies
  • 6.2.1.1 Phospholipid conjugation
  • 6.2.1.2 Glyceride conjugation
  • 6.2.1.3 Fatty acid conjugation
  • 6.2.1.4 Steroid conjugation
  • 6.3 Pharmacokinetics of lipid drug conjugates
  • 6.3.1 Absorption and permeation
  • 6.3.2 Distribution
  • 6.3.2.1 Mechanism of drug distribution and metabolism in lipid drug conjugates
  • 6.3.2.2 Factors influencing distribution
  • 6.3.2.2.1 Physicochemical properties
  • 6.3.2.2.2 Biological factors
  • 6.3.2.2.3 Effect of bonds
  • 6.3.2.2.4 Effect of composition
  • 6.3.3 Metabolism
  • 6.3.3.1 Hydrolysis
  • 6.3.3.2 Redox reactions
  • 6.3.3.3 Transport.
  • 6.3.4 Clearance and elimination of lipid drug conjugates
  • 6.3.4.1 Clearance kinetics
  • 6.4 Clinical implications of lipid drug conjugates and its challenges
  • 6.5 Conclusion and future directions
  • References
  • 7 Production and characterization of various delivery carriers for lipid-drug conjugates
  • 7.1 Introduction
  • 7.2 Delivery carries of lipid-drug conjugates
  • 7.2.1 Emulsion
  • 7.2.2 Liposome
  • 7.2.3 Niosome
  • 7.2.4 Polymeric nanoparticles
  • 7.2.5 Polymeric micelles
  • 7.2.6 Solid lipid nanoparticle
  • 7.2.7 Nanostructured-lipid carrier
  • 7.2.8 Carbon nanotubes
  • 7.2.9 Mesoporous silica nanoparticle
  • 7.3 Production method of lipid-drug conjugate loaded delivery carriers
  • 7.3.1 High pressure homogenization
  • 7.3.2 Microemulsion technique
  • 7.3.3 Solvent emulsification-evaporation
  • 7.3.4 Solvent emulsification-diffusion
  • 7.3.5 Solvent injection
  • 7.3.6 Thin film hydration
  • 7.3.7 Wet milling
  • 7.4 Characterization of lipid-drug conjugates loaded delivery carrier
  • 7.4.1 Fourier transformed infrared spectra analysis
  • 7.4.2 Mass spectroscopy
  • 7.4.3 Nuclear magnetic resonance
  • 7.4.4 Particle size
  • 7.4.5 Polydispersity index
  • 7.4.6 Zeta potential
  • 7.4.7 Electron microscopy analysis
  • 7.4.8 Crystal structure study
  • 7.4.8.1 X-ray powder diffraction analysis
  • 7.4.8.2 Differential scanning calorimetry
  • 7.4.9 Fluorescence spectroscopy
  • 7.4.10 Entrapment efficiency and drug loading
  • 7.4.11 In vitro drug release and release kinetic assessment
  • 7.4.12 Stability testing
  • 7.5 Mechanism of drug release from lipid-drug conjugates based carriers
  • 7.6 Clinical aspects of lipid-drug conjugates based drug development
  • 7.7 Patent review on lipid-drug conjugates
  • 7.8 Regulatory aspects of lipid-drug conjugate nanocarriers
  • 7.9 Conclusion
  • References
  • 2 Applications of lipid-drug conjugates.